China’s Shanghai Pharmaceuticals (SPH, HKG: 2607, SHA: 601607) has declared the termination of clinical trials and subsequent development of I001-B (US), I022 (US), and C012 (US). This decision comes after a comprehensive evaluation of the future market value, business collaboration, and development investment required for these projects. I001-B and I022 are in Phase II stages in the US, while C012 has been cleared for a Phase I study.
I001-B (US): An Oral Renin Inhibitor for Ulcerative Colitis
I001-B (US) is a novel oral renin inhibitor developed for the treatment of mild to moderate ulcerative colitis. The decision to cancel its clinical trials and development in the US has been made, although its Phase II clinical trials in China and clinical studies for I001 in primary mild to moderate hypertension and I001-A in diabetic nephropathy are proceeding as planned.
I022 (US): A Selective Oral Inhibitor for Liposarcoma
I022 (US) is a novel, highly selective oral inhibitor with broad-spectrum anti-tumor effects, intended for the treatment of liposarcoma. Despite the termination of its US trials, its Phase I clinical study in China and clinical studies in combination with other drugs for liposarcoma, posterior line treatment of breast cancer, and brain metastasis of breast cancer are still operational.
C012 (US): A Natural Medicine for Alzheimer’s Disease
C012 (US) is a compound natural medicine developed for the treatment of Alzheimer’s disease. The trials and development for this drug in the US have been halted, aligning with the company’s strategic reassessment of its pipeline.-Fineline Info & Tech
